Corrigendum: Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis

作者：Wei Ren, Hanyu Zhang, Yixin Li, Wu Sun, Hexiang Peng, Huangda Guo, Tianjiao Hou, Mengying Wang, Zhendong Hu, Tao Wu, Baorui Liu · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1611591 · 被引用次数：6 · 研究领域：Cancer Immunotherapy and Biomarkers、Esophageal Cancer Research and Treatment

• please read through all the templates before choosing• pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below.• please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary• submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates.There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake. Corrigendum on: Ren W, Zhang H, Li Y, Sun W, Peng H, Guo H, Hou T, Wang M, Hu Z, Wu T, Liu B. Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis. Front Immunol. 2025 Mar 26;16:1563300. doi: 10.3389/fimmu.2025.1563300. PMID: 40207226